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Abstract: The monitoring of antimicrobial susceptibility of pig pathogens is critical to optimize
antimicrobial treatments and prevent development of resistance with a one-health approach. The aim
of this study was to investigate the antimicrobial susceptibility patterns of swine respiratory pathogens
in Spain from 2017 to 2019. Bacterial isolation and identification were carried out following
standardized methods from samples coming from sacrificed or recently deceased pigs with acute
clinical signs compatible with respiratory tract infections. Minimum inhibitory concentration
(MIC) values were determined using the broth microdilution method containing a total of 10 and
7–8 antimicrobials/concentrations respectively, in accordance with the recommendations presented by
the Clinical and Laboratory Standards Institute (CLSI). The obtained antimicrobial susceptibility varies
between pig respiratory pathogens. Actinobacillus pleuropneumoniae (APP) and Pasteurella multocida
(PM) were highly susceptible (≥90%) to ceftiofur, florfenicol and macrolides (tilmicosin, tildipirosin
and tulathromycin). However, the antimicrobial susceptibility was intermediate (>60% but <90%) for
amoxicillin and enrofloxacin in the case of APP and sulfamethoxazole/trimethropim and tiamulin
in the case of PM. Both bacteria showed low (<60%) antimicrobial susceptibility to doxycycline.
Finally, Bordetella bronchiseptica was highly susceptible only to tildipirosin and tulathromycin (100%)
and its susceptibility for florfenicol was close to 50% and <30% for the rest of the antimicrobial
families tested. These results emphasize the need of determining antimicrobial susceptibility in pig
respiratory cases in order to optimize the antimicrobial treatment in a case-by-case scenario.
Keywords: antimicrobial susceptibility; swine; respiratory pathogens
1. Introduction
The Porcine Respiratory Disease Complex (PRDC) is a syndrome that results from a combination
of infectious and non-infectious factors [1]. Actinobacillus pleuropneumoniae (APP), Pasteurella multocida
(PM), Mycoplasma hyopneumoniae (MH), Bordetella bronchiseptica (BB) and Glaesserella (Haemophilus)
parasuis (GP) are the most common bacterial agents involved. Porcine reproductive and respiratory
syndrome virus (PRRSV), swine influenza virus (SIV) and porcine circovirus type 2 virus (PCV2)
are the most prevalent viral agents [1–6]. On the other hand, many non-infectious predisposing
factors are also involved in PRDC, such as poor environmental conditions, density, stressors, season
of the year, genetic background and production flow (all-in-all out versus continuous flow) [7–9].
As a general approach, preventive medicine programs should be based on applying measures to
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control PRDC in a cost-effective way, such as improving environmental conditions, decreasing density
and stressors, combined with vaccination against the major viral and bacterial infectious etiologic
factors [10]. However, if such measures are not in place or fail, the use of antimicrobials may be needed.
The use of antimicrobials could be necessary to control bacteria involved in PRDC with a
therapeutic or metaphylactic (group medication) goal. In particular, the objective of antimicrobial
therapy is to provide an effective drug to obtain a fast, clinical recovery from the infection in affected
animals but reducing the probability of generating antimicrobial resistance [11]. However, its use is
one of the factors involved in the emergence and spread of bacterial antimicrobial resistance (AR)
from pig origin worldwide [12,13]. Resistant bacteria in humans, food, environment and animals are
interconnected, and exchange may continuously take place between these ecological niches. For this
reason, AR needs to be addressed with a one-health perspective and action plans have been adopted
to address this problem [14]. These plans are based on the development of programs to monitor the
usage of antimicrobial agents in pig medicine and the occurrence of antimicrobial resistance in pigs at
the European level [15,16]. In veterinary medicine, Antimicrobial Susceptibility Testing (AST) data
could predict the clinical outcome of antimicrobial treatment, allowing a rational choice of these drugs
to treat bacterial infections [11,17]. Antimicrobial susceptibility is usually measured using minimum
inhibitory concentration (MIC) that is the lowest antimicrobial concentration that inhibits the growth of
the target bacteria in vitro. Moreover, it is necessary to have valid clinical breakpoints (CB) to correctly
interpret the MIC value obtained for each clinical case. Thus, all the clinical cases with MIC values
below CB could be correctly treated with one antimicrobial at the common registered dose [11].
The Spanish national program to control antimicrobial resistance has been adopted to reduce
the risk of developing antimicrobial resistance since 2014 [16]. One of the points of the program is
focused on reducing the antimicrobial consumption in livestock in order to reduce the prevalence
of resistant bacteria. This antimicrobial consumption has been steadily decreasing in the last years
according to the available European data [15]. Unfortunately, there is little knowledge of antimicrobial
susceptibility patterns for animal pathogenic bacteria in Spain. In this study, we present antimicrobial
susceptibility patterns for some of the most important pig respiratory pathogenic bacteria, collected
during the period 2017–2019 in Spain.
2. Results
Four-hundred samples were received from sow, wean-to-finish and fattening farms across Spain
suffering clinical respiratory cases. In the case of sow farms, the samples were obtained from their
nursery facilities. Bacterial isolation (APP, PM and BB) was only possible in 80.3% (321/400) of the
cases, and in 22% (88/400) of them, it was possible to isolate more than one bacteria. The isolation of
APP and PM and PM and BB was possible in 17.5% (70/400) and 4.5% (18/400) of the cases, respectively.
MIC50, MIC90 and antimicrobial susceptibility for 162, 130 and 29 strains of APP, PM and BB are
described in Tables 1–3, respectively. The number of GP isolates was low (35 strains) and it was not
possible to determine the MIC value because we were unable to grow GP strains with the microdilution
technique in our laboratory. The MIC distribution observed for each microorganism and drug are
shown in Figures 1–5.
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Table 1. Bordetella bronchiseptica (BB), MIC50, MIC90, current recommended clinical breakpoints (CB)
and antimicrobial susceptibility. The MIC50 and MIC90 were determined from the MIC distribution from
29 BB strains isolated from respiratory clinical cases. The antimicrobial susceptibility was calculated as
the percentage of bacterial isolates below CB.
Antimicrobial MIC50 (µg/mL) MIC90 (µg/mL)
Clinical
Breakpoint (CB) 1
(µg/mL)
Antimicrobial
Susceptibility
Based On CB
Amoxicillin 16 16 0.5 0
Ceftiofur 4 4 2 0
Doxycycline 1 2 0.5 27.7
Enrofloxacin 0.5 0.5 0.25 20.7
Florfenicol 2 4 2 51.7
Sulfamethoxazole/
trimethropim & 4 8 0.5 3.4
Tiamulin 64 64 16 0
Tildipirosin 4 8 8 100
Tilmicosin 32 64 16 27.6
Tulathromycin 8 8 16 100
1 Florfenicol, tildipirosin and tulathromycin CB were obtained from CLSI M100 2018 and CLSI VETO8 4th ed.,
2018. The rest of the CB were extrapolated from Pasteurella multocida (Table 3). & MIC represented in the table is for
trimethropin. Sulfamethoxazole/trimethropim ratio tested is 19:1.
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Figure 1. Minimum inhibitory concentration (MIC, μg/mL) distribution of amoxicillin (A) and 
ceftiofur (B) for Actinobacillus pleuropneumoniae (APP) and Pasteurella multocida (PM) isolated from 
lungs of pigs with respiratory symptoms.  
 
Figure 2. Minimum inhibitory concentration (MIC, μg/mL) distribution of enrofloxacin (A) and 
doxycycline (B) for Actinobacillus pleuropneumoniae (APP) and Pasteurella multocida (PM) isolated from 
lungs of pigs with respiratory symptoms.  
Figure 1. Minimum inhibitory concentration (MIC, µg/mL) distribution of amoxicillin (A) and ceftiofur
(B) for Actinobacillus pleuropneumoniae (APP) and Pasteurella multocida (PM) isolated from lungs of pigs
with respiratory symptoms.
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Figure 3. Minimum inhibitory concentration (MIC, μg/mL) distribution of florfenicol (A) and 
sulfamethoxazole/trimethoprim (B) for Actinobacillus pleuropneumoniae (APP) and Pasteurella multocida 
(PM) isolated from lungs of pigs with respiratory symptoms. In the case of 
sulfametoxazole/trimethoprim, the MIC value for trimethoprim is represented.  
 
Figure 3. Minimum inhibitory concentration (MIC, µg/mL) distribution of florfenicol (A) and
sulfamethoxazole/trimethoprim (B) for Actinobacillus pleuropneumoniae (APP) and Pasteurella multocida
(PM) isolated from lungs of pigs with respiratory symptoms. In the case of sulfametoxazole/trimethoprim,
the MIC value for trimethoprim is represented.
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Table 1. Actinobacillus pleuropneumoniae (APP), MIC50, MIC90, current recommended clinical 
breakpoints (CB) and antimicrobial susceptibility. The MIC50 and MIC90 were determined from the 
MIC distribution from 162 APP strains isolated from respiratory clinical cases. The antimicrobial 
susceptibility was calculated as the percentage of bacterial isolates below CB. 
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Breakpoint 
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Doxycycline 1 4 0.5+ 35.7 
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Florfenicol 0.25 0.25 2 97.0 
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Figure 5. Minimum inhibitory concentration (MIC, µg/mL) distribution of tulathromycin (A) and
tilmicosin (B) for Actinobacillus pleuropneumoniae (APP) and Pasteurella multocida (PM) isolated from
lungs of pigs with respiratory symptoms.
Antibiotics 2020, 9, 402 6 of 13
APP and PM MIC distributions were very similar for ceftiofur (Figure 1B) and florfenicol
(Figure 3A). On the other hand, the APP and PM MIC distributions were different for the following
antimicrobials: amoxicillin (Figure 1A), enrofloxacin (Figure 2A), sulfamethoxazole/trimethoprim
(Figure 3B), doxycycline (Figure 2B), tildipirosin and tiamulin (Figure 4A,B) and tulathromycin and
tilmicosin (Figure 5A,B).
The isolates of APP were highly susceptible (≥90%) to macrolides (tildipirosin, tulathromycin
and tilmicosin), tiamulin, florfenicol, sulfamethoxazole/trimethropim and ceftiofur. However, the
antimicrobial susceptibility was intermediate (around 72%) for amoxicillin and enrofloxacin and
low (35.7%) for doxycycline. Pasteurella multocida showed high susceptibility (≥90%) to macrolides
(tildipirosin, tulathromycin and tilmicosin), florfenicol, enrofloxacin, amoxicillin and ceftiofur. However,
PM antimicrobial susceptibility was intermediate (74.7%) for sulfamethoxazole/trimethropim and
tiamulin (60.8%) and low (51.5%) for doxycycline. Thus, in general terms, APP and PM were susceptible
to many families of antimicrobials, whereas BB was highly susceptible (100%) only to tildipirosin and
tulathromycin. On the other hand, BB susceptibility for florfenicol was close to 50% and <30% for the
rest of the antimicrobial families tested (Tables 1–3).
3. Discussion
There is a scarcity of updated information about antimicrobial susceptibility among porcine
pathogens in Spain because there is no official program for their surveillance. The current study aims
to address this gap by determining antimicrobial susceptibility, through determining MICs, of ten
antimicrobials to three major respiratory tract pathogens recovered, prior to antibiotic treatment,
from diseased pigs across Spain. In this case, we have focused on the antimicrobials most frequently
used to treat respiratory disease in pigs.
The measurement of antimicrobial susceptibility is carried out by MIC determination that is
more reproducible and comparable between laboratories [11] than disk diffusion techniques due
to concerns about disk quality, performance issues [18,19] and variability intrinsically associated
to some antimicrobials for the disk diffusion technique [20]. The MIC is the lowest antimicrobial
concentration that inhibits in vitro the growth of the target bacteria in specific conditions of in vitro
incubation. In this study, the antimicrobial susceptibility has been determined using international
guidelines on antimicrobial susceptibility determination [21,22] that cannot be directly compared with
other studies only based on disk diffusion techniques [20]. This methodology does not emulate the
natural biophase in which bacteria grow in vivo, such as blood, interstitial or intracellular fluid. In any
case, antimicrobial sensitivity testing in vitro is used to provide information concerning the efficacy
of antimicrobial agents in vivo and thus determine whether an antibiotic is suitable or not to treat
a specific condition [23], but MIC determination, as any technique, has weaknesses that should be
outweighed [24]. Thus, there is an interesting scientific discussion about the usefulness of MIC to
foresee the clinical outcome. Some authors recently have proposed to consider both pathogen- (MIC)
and patient-specific drug exposure information to predict treatment success in humans. If both pieces
of information are taken into account, it will change how antimicrobials are selected and it will allow
optimizing the treatment through precision medicine [25]. Unfortunately, this approach is far away
from the “everyday” veterinary medicine, where posology regimens of antimicrobials are fixed for
each animal species and bacteria to be treated (registered dose for a veterinary medicinal product).
Furthermore, the selection of the antimicrobial is even stricter due to the existence of withdrawal
periods in livestock to assure food safety that exclude off-label use of antimicrobials to apply precision
medicine [25].
Comparison of antimicrobial susceptibility from other laboratories must be carried out with
caution due to inconsistencies in methodology (MIC versus disk diffusion technique), selection
of antimicrobial substances in the test panel and variations in interpretation criteria for clinical
breakpoints. In our study, the isolates of APP were highly susceptible for macrolides (tildipirosin,
tilmicosin and tulathromycin), tiamulin, florfenicol, sulfamethoxazole/trimethropim and ceftiofur.
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However, the antimicrobial susceptibility was intermediate for amoxicillin and enrofloxacin, and low
for doxycycline. This antimicrobial susceptibility pattern described for APP in this study agrees with
results obtained by Spanish researchers with strains collected from 1997 [26]. These results could be
surprising due to the historic consumption of antimicrobials in Spain and the authors recommend
not directly linking the use of antimicrobials with the presence of antimicrobial resistance for any
drug–microorganism combination. Moreover, our results are quite similar for isolates from other
European countries with some differences [27,28]. Overall, there are still good opportunities to treat
infections by APP with antimicrobials, but the presence of strains resistant to doxycycline, amoxicillin
and enrofloxacin in Spain highlight the importance of monitoring antimicrobial susceptibility and
select the most suitable antimicrobial in a case-by-case situation.
In our study, the isolates of PM were highly susceptible for macrolides (tildipirosin, tilmicosin and
tulathromycin), florfenicol, enrofloxacin, amoxicillin and ceftiofur. However, the antimicrobial
susceptibility was intermediate for sulfamethoxazole/trimethropim and tiamulin, and low for
doxycycline. Thus, the antimicrobial susceptibility pattern is different from that described for
APP in spite of the fact that both bacteria are respiratory ones. Again, these results highlight
that monitoring of antimicrobial susceptibility must be carried out for each drug–microorganism
combination. Moreover, the antimicrobial susceptibility pattern described in our study is very similar
to the pattern described by Spanish researchers with strains collected from 1987 [29] for macrolides
(>97%), ceftiofur (100%), ampicillin (98%), enrofloxacin (100%), tiamulin (50%) and florfenicol (100%),
and by European researchers in a multi-country study to determine the antimicrobial susceptibility
of PM in pigs for ceftiofur (100%), enrofloxacin (100%), florfenicol (99.3%), tetracycline (65.8%) and
macrolides (>90%) [30]. Thus, the antimicrobial susceptibility of PM seems to have not changed
significantly across time, at least, in Europe. This result could be surprising taking into account the
enormous variability in the consumption of antimicrobials in livestock across Europe and the authors
recommend, again, not directly linking the use of antimicrobials with the presence of antimicrobial
resistance for any drug–microorganism combination.
Bordetella bronchiseptica causes a mild or non-progressive inflammation in the nasal cavity that
usually needs no treatment. However, if the bacterium is co-infecting with toxigenic PM, it can lead to
severe progressive atrophic rhinitis [31]. Moreover, BB may cause pneumonia in young piglets in some
cases. In our study, the number of BB strains was quite low to precisely define their MIC distributions.
Thus, our results of antimicrobial susceptibility for BB must be interpreted with caution. Moreover,
there is a lack of approved clinical breakpoints for many antimicrobials with this bacterium, making
comparison with other studies extremely complicated. Bordetella bronchiseptica has been described to
be intrinsically resistant to ampicillin due to production of beta-lactamases [32,33] and our results
agree with this affirmation not only for amoxicillin but also for ceftiofur. In our case, the isolates
had extremely high MIC values for doxycycline that exclude them as a therapeutic option to treat BB
infection. This lack of antimicrobial susceptibility agrees with Speakman et al. [34] who described a
plasmid-encoded tetracycline resistance gene, tetC, for this bacterium. Finally, macrolides are also the
most susceptible family against BB in Denmark [28], and Dayao et al. [35] also reported no resistance
to tulathromycin in Australia.
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Table 2. Actinobacillus pleuropneumoniae (APP), MIC50, MIC90, current recommended clinical breakpoints
(CB) and antimicrobial susceptibility. The MIC50 and MIC90 were determined from the MIC distribution
from 162 APP strains isolated from respiratory clinical cases. The antimicrobial susceptibility was
calculated as the percentage of bacterial isolates below CB.
Antimicrobial MIC50 (µg/mL) MIC90 (µg/mL)
Clinical
Breakpoint (CB) 1
(µg/mL)
Antimicrobial
Susceptibility
Based on CB
Amoxicillin 0.25 16 0.5 $ 72.2
Ceftiofur 0.06 0.06 2 100
Doxycycline 1 4 0.5 + 35.7
Enrofloxacin 0.06 1 0.25 72.2
Florfenicol 0.25 0.25 2 97.0
Sulfamethoxazole/
trimethropim & 0.125 2 0.5 88.9
Tiamulin 16 16 16 98.8
Tildipirosin 4 8 16 99.4
Tilmicosin 8 16 16 99.4
Tulathromycin 32 64 64 100
1 All clinical breakpoints were obtained from Clinical and Laboratory Standards Institute (CLSI) M100 2018 and
CLSI VETO8 4th ed., 2018, with the following clarifications: $ Schwarz et al. (2008) [36]. + Extrapolated from
tetracycline. & MIC represented in the table is for trimethropin. Sulfamethoxazole/trimethropim ratio tested is 19:1.
Table 3. Pasteurella multocida (PM), MIC50, MIC90, current recommended clinical breakpoints (CB) and
antimicrobial susceptibility. The MIC50 and MIC90 were determined from the MIC distribution from
130 PM strains isolated from respiratory clinical cases. The antimicrobial susceptibility was calculated
as the percentage of bacterial isolates below CB.
Antimicrobial MIC50 (µg/mL) MIC90 (µg/mL)
Clinical
Breakpoint (CB) 1
(µg/mL)
Antimicrobial
Susceptibility
Based On CB
Amoxicillin 0.25 0.5 0.5 $ 96.2
Ceftiofur 0.06 0.12 2 100
Doxycycline 0.5 4 0.5 + 51.5
Enrofloxacin 0.03 0.06 0.25 98.5
Florfenicol 0.5 0.5 2 100
Sulfamethoxazole/
trimethropim & 0.12 4 0.5 74.7
Tiamulin 16 32 16 60.8
Tildipirosin 1 2 4 97.7
Tilmicosin 8 16 16 94.6
Tulathromycin 2 4 16 100
1 All clinical breakpoints were obtained from CLSI M100 2018 and CLSI VETO8 4th ed., 2018 with the following
clarifications: $ Schwarz et al. (2008) [36]. + Extrapolated from tetracycline. & MIC represented in the table is for
trimethropin. Sulfamethoxazole/trimethropim ratio tested is 19:1.
It is necessary to have valid information about CB to correctly interpret the MIC value obtained
in each clinical case. Thus, all the clinical cases with MIC values below CB could be treated with the
antimicrobial, at the registered dose, with a high success rate. Unfortunately, there are no clinical
veterinary breakpoints available for all the antimicrobials and bacteria for pigs. In our study, we have
used well-established CLSI clinical breakpoints for seven out of ten antimicrobials. However, CLSI
veterinary breakpoints for sulfamethoxazole/trimethropim and Pasteurellaceae have not been set. In this
study, the CLSI CB available for Streptococcus suis (0.5 µg/mL) have been used. This value exactly
agrees with the CB used by El Garch et al. [30] in a study to monitor the antimicrobial susceptibility for
sulfamethoxazole/trimethropim of porcine pathogens in Europe, making results directly comparable.
These authors carried out this extrapolation due to the high similarity between Haemophilus influenziae
and respiratory pathogens in pigs. Moreover, The CLSI clinical breakpoint for amoxicillin (0.5 µg/mL)
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has been obtained from the literature [36]. This CB value for amoxicillin is equal to the CLSI CB
for ampicillin that belongs to the same antimicrobial family (beta-lactam antimicrobials). However,
Rey et al. [37] proposed that the CB breakpoint (obtained through pharmacokinetics/pharmacodynamic
analysis) for amoxicillin, administered by the intramuscular route, could be as low as 0.125 µg/mL
for pig respiratory pathogens. If we had used this proposed breakpoint instead of the chosen one
(0.5 µg/mL), the percentage of antimicrobial susceptibility for APP and PM would have been 26% and
7% respectively, which is extremely different from the results shown for this antimicrobial in this paper.
Thus, there is an urgent need to have CLSI CB breakpoints available for every antimicrobial/bacteria and
feedback from swine practitioners when using these antimicrobials at the registered dose [38]. In this
sense, the collaboration between microbiologists, pharmacologists and swine practitioners is highly
recommended. Finally, CB for doxycycline was extrapolated from CLSI CB available for tetracycline and
porcine respiratory pathogens. In general, the percentage of antimicrobial susceptibility determined in
our study is comparable with any other study published using CLSI clinical breakpoints. In the case of
doxycycline, amoxicillin and sulfamethoxazole/trimethropim, our results must be compared checking
the CB used by other authors before making direct comparisons between them. Finally, antimicrobial
susceptibility pattern can change with time [28] and this is one of the main reasons to determine it
across time in order to select the most suitable antimicrobial, taking into account efficacy criteria and
the one-health approach [14].
4. Materials and Methods
4.1. Clinical Samples
Samples were drawn from diseased or recently deceased pigs from farms across Spain showing
acute clinical signs of respiratory tract infections that had not been exposed to antimicrobial treatment
for, at least, 15 days prior to sampling between the years 2017 and 2019. Thus, the sampled animals were
between 3 and 24 weeks old, the pigs had overt clinical respiratory signs with or without depression
and/or hyperthermia (>39.8 ◦C) and the mortality rate increased significantly, versus the previous
baseline situation, due mainly to respiratory causes at farm level. For each clinical case, samples of
lungs of two recently deceased pigs (<12 h) were submitted under refrigeration to the laboratory
(to increase possibility to isolation). If, during the veterinary visit, there were no recently dead pigs
suitable for sampling, at least two animals with acute respiratory signs were humanely sacrificed and
lung samples were drawn. In any case, only one isolate per animal/herd was included in the study.
All experimental procedures were approved by the Ethics Committee for Animal Experimentation of
the University of Lleida and performed in accordance with authorization 10343 issued by the Catalan
Department of Agriculture, Livestock, Fisheries and Food (Section of biodiversity and hunting).
4.2. Bacterial Isolation and Identification
Clinical specimens were cultured aseptically onto blood agar (Columbia agar with 5% Sheep
blood, 254005 BD), chocolate agar (GC II agar with IsoVitaleX, 254060, BD, Franklin Lakes NJ, USA))
and MacConkey agar (4016702, Biolife Italiana Srl, Milano, Italy) and incubated at 35–37 ◦C in aerobic
conditions with 5–10% CO2 for 24–48 hours. Identification of isolates (APP, PM, BB and GP) was
carried out by matrix-assisted laser desorption ionization-time of flight (MALDI-TOF Biotyper System,
Bruker Daltonics, Bremen, Germany). Individual strains were stored at −80 ◦C in brain heart infusion
(CM1135, Oxoid, Madrid, Spain) with 30% of glycerol (G9012, Sigma-Aldrich, Madrid, Spain).
4.3. Antimicrobial Sensitivity Testing
MIC values were determined using the broth microdilution method by means of customized
96-well microtiter plates (Sensititre, Trek diagnostic Systems Inc., East Grinstead, UK) containing a
total of 10 and 7–8 antimicrobials/concentrations respectively, in accordance with the recommendations
presented by the Clinical and Laboratory Standards Institute (CLSI) [21,22]. The antimicrobials tested
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included amoxicillin, ceftiofur, doxycycline, enrofloxacin, florfenicol, sulfamethoxazole/trimethoprim,
tiamulin, tilmicosin, tildipirosin and tulathromycin. This antimicrobial panel was selected to represent
common compounds licensed for treatment of pig respiratory diseases in practice.
Bacteria were thawed, cultured on chocolate agar and incubated at 35–37 ◦C in ambient air
(or with 5−10% CO2 for APP) for 18–24 h. Three to five colonies were picked and emulsified in
demineralized water (or cation-adjusted Mueller–Hinton broth (CAMHB) for APP) to obtain a turbidity
of 0.5 McFarland standard (Sensititre™ nephelometer V3011). Suspensions were further diluted in
CAMHB (for PM and BB) or Veterinary Fastidious Medium (in the case of APP) to reach a final
inoculum concentration of 5 × 105 colony forming units (cfu)/mL (Table 4). Then, the Sensititre panel
was reconstituted by adding 100 µL/well of the inoculum. Plates containing PM and BB isolates were
incubated at 35 ± 2 ◦C for 18−20 h. In the case of APP isolates, plates were covered with a perforated
seal and incubated at 35 ± 2 ◦C, with 5−10% CO2 for 20–24 h [21,22]. The antibiotic panels were read
manually using Sensititre™ Vizion (V2021) and the MIC value was established as the lowest drug
concentration inhibiting visible growth. For each strain tested, a colony count and a purity check were
performed following CLSI and manufacturer recommendations. Moreover, quality control strains were
also included in all susceptibility testing runs. Thus, Actinobacillus pleuropneumoniae (ATCC 27090™)
and Escherichia coli (ATCC 25922™) were included as quality control [21,22]. The MICs of the quality
control strains had to be within acceptable CLSI ranges to accept the results obtained in the laboratory.
Table 4. Details of the conditions used to carry out minimum inhibitory concentration (MIC)
determination using the broth microdilution method by means of customized 96-well microtiter
plates (Sensititre, Trek diagnostic Systems Inc., East Grinstead, UK).
Microorganism
0.5 McFarland
Suspension
Medium
Broth FinalInoculum
Plate
Reconstitution
Incubation
Conditions
Pasteurella
multocida and
Bordetella
bronchiseptica
Water CAMHB 5 × 105 cfu/mL 100 µL
35 ± 2 ◦C
18−24 h
Non-CO2
incubator
Actinobacillus
pleuropneumoniae CAMHB VFM 5 × 105 cfu/mL 100 µL
35 ± 2 ◦C
20−24 h
CO2 incubator
perforated seal
CAMHB—Cation-adjusted Mueller–Hinton Broth. VFM—Veterinary Fastious Medium. cfu—colony forming units.
4.4. Data Analysis
All the clinical cases with MIC values below CB were classified as susceptible because they
could be treated with the antimicrobial, at the registered dose, with a high success rate. The results
of the sensitivity tests are presented as MIC distributions and these were determined for each
species–antimicrobial combination. MIC50 and MIC90 were defined as MICs inhibiting 50% and
90% of the strains, respectively. Clinical breakpoints from CLSI were used [21,22] to determine
antimicrobial susceptibility. However, CLSI veterinary breakpoints for sulfamethoxazole/trimethropim
and Pasteurellaceae have not been set. Thus, the CLSI CB available for Streptococcus suis (0.5 µg/mL)
and sulfamethoxazole/trimethropim have been used in this study. The clinical breakpoint for
amoxicillin (0.5 µg/mL) has been obtained from the literature [36] and CLSI CB available for
tetracycline (0.5 µg/mL) and porcine respiratory pathogens was extrapolated for doxycycline [21,22].
The antimicrobial susceptibility was considered high at levels≥90% and low at levels≤60%, as described
by Holmer et al. [28].
Antibiotics 2020, 9, 402 11 of 13
5. Conclusions
The obtained antimicrobial susceptibility varies between pig respiratory pathogens. Actinobacillus
pleuropneumoniae and Pasteurella multocida were highly susceptible to ceftiofur, florfenicol and macrolides.
However, the antimicrobial susceptibility was intermediate for amoxicillin and enrofloxacin in the case
of APP and sulfamethoxazole/trimethropim and tiamulin in the case of PM. Both bacteria showed
low antimicrobial susceptibility to doxycycline. Finally, Bordetella bronchiseptica was highly susceptible
only to tildipirosin and tulathromycin and its susceptibility for florfenicol was close to 50% and <30%
for the rest of the antimicrobial families tested. These results emphasize the need for determining
antimicrobial susceptibility in pig respiratory cases in order to optimize the antimicrobial treatment in
a case-by-case scenario and provide a robust criteria to select the most suitable antimicrobials, taking
into account the one-health approach. On the other hand, there is an urgent need to have CLSI CB
breakpoints available for every antimicrobial/bacteria and feedback from swine practitioners when
using these antimicrobials at the registered dose.
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